Antibiotics Partnering Terms and Agreements

Date: January 1, 2015
Pages: 419
Price:
US$ 1,995.00
License [?]:
Publisher: CurrentPartnering
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), CD-ROM Mail Delivery, E-mail Delivery (Word)
ID: A5A047CBCF3EN
Leaflet:

Download PDF Leaflet

Antibiotics Partnering Terms and Agreements
SUMMARY

The Antibiotics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibiotic partnering deals and agreements entered into by the worlds leading healthcare companies.

DESCRIPTION

The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.
  • Trends in antibiotics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Antibiotics partnering contract documents
  • Top antibiotics deals by value
The Antibiotics Partnering Terms and Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:
  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 150 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with deal announced along with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since 2009 organized by antibiotics technology focus. The chapter includes deals listed by antibiotics and broken down into individual type of antibiotics- aminoglycosides, cephalosporin, clindamycin, macrolides, metronidazole, penicillin, quinolones and tetracycline. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2009.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z , stage of development, deal type and therapy focus, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope

Antibiotics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Antibiotics Partnering Terms and Agreements includes:
  • Trends in antibiotics dealmaking in the biopharma industry since 2009
  • Analysis of antibiotics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life antibiotics deals
  • Access to over 150 antibiotics deal records and contract documents where available
  • The leading antibody deals by value since 2009
  • Most active antibiotics dealmakers since 2009
  • The leading antibiotics partnering resources
In Antibiotics Partnering Terms and Agreements, the available contracts are listed by:
  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

BENEFITS

Antibiotics Partnering Terms and Agreements provides the reader with the following key benefits:
  • In-depth understanding of antibiotics deal trends since 2009
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of antibiotics agreements with numerous real life case studies
  • Comprehensive access to over 150 antibiotics deals entered into by the world’s biopharma companies, together with real world clause examples and contracts where available
  • Full listing of antibiotics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading antibiotics deals by value since 2009
  • Identify the most active antibiotics dealmakers since 2009
  • Detailed access to actual antibiotics contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a antibiotics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
EXECUTIVE SUMMARY

CHAPTER 1 – INTRODUCTION

CHAPTER 2 – TRENDS IN ANTIBIOTICS DEALMAKING

2.1. Introduction
2.2. Antibiotics partnering over the years
2.3. Big pharma antibiotics dealmaking activity
2.4. Big biotech antibiotics dealmaking activity
2.5. Most active in antibiotics partnering
2.6. Antibiotics partnering by deal type
2.7. Antibiotics partnering by disease type
2.8. Partnering by antibiotics technology type
2.9. Antibiotics partnering by industry sector
2.10. Average deal terms for antibiotics partnering
  2.10.1 Antibiotics headline values
  2.10.2 Antibiotics upfront payments
  2.10.3 Antibiotics milestone payments
  2.10.4 Antibiotics royalty rates
2.11. The anatomy of antibiotics partnering
2.12. The anatomy of an antibiotics deal
2.12. a. Case study 1: RRD International & Dipexium Pharmaceuticals –Feb 03 2014
2.12.b. Case study 2: Hospira & Cempra Pharmaceutical- July 01 2013
2.12.c. Case study 3: Astellas & Optimer Pharmaceuticals- Feb 7 2011

CHAPTER 3 – LEADING ANTIBIOTICS DEALS

3.1. Introduction
3.2. Top antibiotics deals by value

CHAPTER 4 – BIG PHARMA ANTIBIOTICS DEALS

4.1. Introduction
4.2. How to use big pharma antibiotics partnering deals
4.3. Big pharma antibiotics partnering company profiles

CHAPTER 5 – BIG BIOTECH ANTIBIOTICS DEALS

5.1. Introduction
5.2. How to use big biotech partnering deals
5.3. Big biotech antibiotics partnering company profiles

CHAPTER 6 – ANTIBIOTICS PARTNERING CONTRACTS DIRECTORY

6.1. Introduction
6.2. Antibiotics partnering with contract documents by company A-Z
6.3. Antibiotics partnering with contract documents by deal type
6.4. Antibiotics partnering with contract documents by therapy area

CHAPTER 7 – ANTIBIOTICS DEALMAKING BY TECHNOLOGY TYPE

7.1. Introduction
7.2. Deals by antibiotics type
Antibiotics
Note: For full list of antibiotics deals announced - see appendices 1-4

APPENDICES

Appendix 1- Antibiotics deals directory by company A-Z
Appendix 2- Antibiotics deals directory by stage of development
Appendix 3- Antibiotics deals directory by deal type
Appendix 4- Antibiotics deals directory by therapy area
Appendix 5 – Antibiotics partnering resource center
Online antibiotics partnering
Appendix 6 – Antibiotics partnering events
Further reading on antibiotics dealmaking

ABOUT WILDWOOD VENTURES

Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

LIST OF FIGURES

Figure 1: Antibiotics partnering since 2009
Figure 2: Big pharma – top 50 – antibiotics deals 2009-2014
Figure 3: Big pharma antibiotics deal frequency – 2009 to 2014
Figure 4: Big biotech – top 50 – antibiotics deals 2009-2014
Figure 5: Big biotech antibiotics deal frequency – 2009 to 2014
Figure 6: Active antibiotics dealmaking activity– 2009 to 2014
Figure 7: Antibiotics partnering by deal type since 2009
Figure 8: Antibiotics partnering by disease type since 2009
Figure 9: Antibiotics partnering by technology type since 2009
Figure 10: Antibiotics partnering by industry sector since 2009
Figure 11: Antibiotics deals with a headline value by year- 2014
Figure 12: Antibiotics deals with a headline value by year- 2013
Figure 13: Antibiotics deals with a headline value by year- 2012
Figure 14: Antibiotics deals with a headline value by year- 2011
Figure 15: Antibiotics deals with a headline value by year- 2010
Figure 16: Antibiotics deals with a headline value by year- 2009
Figure 17: Summary median headline value by year, 2009-2014
Figure 18: Antibiotics deals with an upfront value by year- 2014
Figure 19: Antibiotics deals with an upfront value by year- 2013
Figure 20: Antibiotics deals with an upfront value by year- 2012
Figure 21: Antibiotics deals with an upfront value by year- 2011
Figure 22: Antibiotics deals with an upfront value by year- 2010
Figure 23: Antibiotics deals with an upfront value by year- 2009
Figure 24: Summary median upfront value by year, 2009-2014
Figure 25: Antibiotics deals with a milestone value by year- 2014
Figure 26: Antibiotics deals with a milestone value by year- 2013
Figure 27: Antibiotics deals with a milestone value by year- 2012
Figure 28: Antibiotics deals with a milestone value by year- 2011
Figure 29: Antibiotics deals with a milestone value by year- 2010
Figure 30: Antibiotics deals with a milestone value by year- 2009
Figure 31: Antibiotics deals with a royalty rate value by year- 2014
Figure 32: Antibiotics deals with a royalty rate value by year- 2013
Figure 33: Antibiotics deals with a royalty rate value by year- 2012
Figure 34: Antibiotics deals with a royalty rate value by year- 2011
Figure 35: Antibiotics deals with a royalty rate value by year- 2010
Figure 36: Antibiotics deals with a royalty rate value by year- 2009
Figure 37: Summary median royalty rate by year, 2009-2014
Figure 38: Components of the typical antibiotics deal structure
Figure 39: Top antibiotics deals by value since 2009
Figure 40: Online partnering resources
Figure 41: Forthcoming partnering events
Skip to top


Ask Your Question

Antibiotics Partnering Terms and Agreements
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: